Image: Leigh Prather, via Shutterstock
Commission says it will “study judgment and its implications” for case involving sequencing company Illumina
The EU’s top court has ruled that the European Commission overreached in its actions relating to an acquisition deal involving two US-based firms, for which the EU institution tried to levy a fine of hundreds of millions of euros.
Illumina, a company that makes technologies for sequencing genetic material, wanted to acquire Grail, which makes tests for diagnosing cancer and which it had previously spun out.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.